# Trade Mark Journal No.2025/031 1 August 2025

## WO0000001864199 (5,42,44)

Office of origin: United States of America

Date of International Registration:29 May 2025
Date of designation in the UK: 29 May 2025

The mark consists of four lines with curved top and bottom edges that become progressively larger from left to right and form the overall shape of a conical seashell. The lines appear in dark purple, purple, dark orange, orange from left to right and are positioned above the word CRENESSITY.

The mark contains the colours dark purple, purple, dark orange, and orange which are claimed as a feature of the mark.

The mark consists of four lines with curved top and bottom edges that become progressively larger from left to right and form the overall shape of a conical seashell. The lines appear in dark purple, purple, dark orange, orange from left to right and are positioned above the word CRENESSITY.

International priority date claimed: 29 January 2025 (United States of America) (99021889)

Class 5
  Pharmaceutical preparations for the treatment of adrenal insufficiency; pharmaceutical preparations for the treatment of hormonal and genetic diseases, disorders and conditions; pharmaceutical preparations for the diagnosis, prevention and treatment of endocrine diseases and disorders; pharmaceutical preparations for the treatment of congenital adrenal hyperplasia; pharmaceuticals for the treatment of rare and orphan hormonal and genetic diseases, disorders and conditions.
Class 42
  Providing medical research information; providing medical research information in the field of pharmaceuticals and clinical trials focusing on congenital adrenal hyperplasia and other endocrine diseases and disorders; scientific research in the nature of conducting clinical trials for pharmaceutical preparations for the treatment of congenital adrenal hyperplasia and other endocrine diseases and disorders, for others; conducting post-authorization pharmaceutical research for the marketing of pharmaceutical preparations and evaluating epidemiological results.
Class 44
  Providing medical information; providing medical information to patients, medical professionals, and insurance companies in the field of congenital adrenal hyperplasia and other endocrine diseases and disorders; on-line information services, namely, providing medical information to patients, medical professionals, and insurance companies in the field of congenital adrenal hyperplasia and other endocrine diseases and disorders.

Neurocrine Biosciences, Inc.

Representative: Nadine H. Jacobson Fross Zelnick Lehrman & Zissu, P.C., 151 West 42nd St., 17th Fl., New York NY 10036, UNITED STATES OF AMERICA